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cance for reduction in antibiotic ﬁlls. The provider survey
showed statistically signiﬁcant self-reported differences between
the intervention and control clinic providers in the hypothesized
direction for all three outcome measures. Signiﬁcant differences
in outcomes were seen by provider type (family practice, urgent
care, or pediatrician). CONCLUSIONS: Analyses of claims data
showed a reduction in the diagnosis of AOM and increased ﬁlls
of analgesic drops for pain, as hypothesized. Improvement was
more marked in the self-reports than in the claims data. Outcome
differences were mediated by provider specialty.
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DELIVERY SYSTEM
Gunter MJ1, Beaton SJ1, Paez KA1, Chilton L2, Dougherty D3
1Lovelace Clinic Foundation, Albuquerque, NM, USA; 2Lovelace 
Sandia Health System, Albuquerque, NM, USA; 3Agency for
Healthcare Research and Quality (AHRQ), Rockville, MD, USA
OBJECTIVES: Numerous studies have evaluated the impact of
various guideline implementation interventions and have 
found different results for seemingly similar interventions. To
investigate this issue, we conducted a process evaluation of a
multi-faceted otitis media guideline intervention that examined
intervention details, degree of provider exposure, and provider
perceptions. METHODS: Ten primary care clinics in a south-
western integrated delivery system were organized into matched
pairs and assigned to control status (mailed guidelines only) or
intervention status (provider exposure to formal education,
guideline tools, reinforcement messages, and feedback).
Researchers documented the nature and timing of the multiple
interventions, degree of intervention exposure (training atten-
dance by intervention clinic providers, provider self-report of
intervention exposure), and experience of providers (provider
ranking of each intervention’s value). RESULTS: Training atten-
dance varied signiﬁcantly across intervention clinics and by spe-
cialty, with family practitioners having higher attendance (64%)
than urgent care providers (57%) or pediatricians (47%).
Providers attending the formal training were more guideline-
compliant pre-intervention than those who did not attend. Of
the ten interventions, two-thirds or more of the providers
recalled having seen or participated in: the guidelines, the formal
training, the repair of otoscopes, the laminated guideline
summary card, and the ofﬁce poster. The interventions ranked
as highest in value were: repair of the otoscopes, the formal train-
ing, and the guidelines. CONCLUSIONS: The different pre-
intervention practice patterns found for providers who attended
the training vs. those who did not suggests the importance of
adjusting for this factor in analyzing intervention impact on
guideline compliance. The most concrete and basic interven-
tion—repair of the otoscopes—was best remembered and most
valued by the providers, perhaps because it is central to the accu-
rate diagnosis of otitis. The latter further suggests the importance
of a needs assessment to tailor the speciﬁc interventions to the
particular practice setting.
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OBJECTIVES: To investigate comorbidities associated with
glaucoma and trend of glaucoma incidence in the California
Medicaid population. METHODS: A retrospective case-control
study was conducted using 20% sample of the Medi-Cal admin-
istrative claims data from January 1, 1995 to December 31,
2002. Patients with glaucoma were identiﬁed using ICD-9 diag-
nosis (ICD-9 = 365.xx) and were 1 :3 randomly matched to a
cohort without glaucoma based on age and gender. Eligibility
was measured by the number of enrollment months. Relative risk
(RR) was calculated to estimate the risk of glaucoma patients to
a proﬁle of 25 comorbidities set forth by AHRQ. RESULTS: A
total of 32,395 glaucoma patients were matched to 97,185 con-
trols. The mean age was 65.5 (+/-19.8) and 34.9% were male.
Over the eight years of study period, glaucoma patients had 
signiﬁcantly longer length of Medi-Cal eligibility than non-
glaucoma patients (71.6 vs. 50.8 months, p < 0.0001). African
Americans were at signiﬁcantly higher risk of glaucoma (RR =
1.53) and Hispanics had lower risk (RR = 0.74). Patients with
glaucoma were at signiﬁcantly higher risk for most diseases, such
as rheumatoid arthritis (RR = 1.49), hypothyroidism (RR =
1.39), diabetes (RR = 1.35), valvular diseases (RR = 1.35),
depression (RR = 1.32) and peripheral vascular diseases (RR =
1.26). The yearly incidence rate for glaucoma decreased over
time from 48.5 per 10,000 person-year in 1995 to 18.6 per
10,000 person-year in 2002. The average incidence rate for 
glaucoma patients was 29.0 per 10,000 person-year during 
the eight-year study duration. CONCLUSIONS: The glaucoma 
population suffers from numerous comorbidities, although it is
not clear whether they affect treatment alternatives. The inci-
dence rate of glaucoma sharply declined from 1995 to 2002 in
Medi-Cal population.
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OBJECTIVES: The objective of this study was to determine the
frequency and describe the reasons for changes in pharma-
cotherapy in the treatment of primary open-angle glaucoma
(POAG), normal tension glaucoma (NTG), and ocular hyper-
tension (OH). METHODS: Retrospective analysis was con-
ducted of the Glasgow Royal Inﬁrmary Glaucoma Database. The
database was comprised of computerized medical records of all
POAG, NTG, and OH patients treated at the Glasgow Royal
Inﬁrmary from 1981 to present, representing 745 patients or
>5000 treatment years. Data elements recorded for each patient
included demographics, diagnosis, and treatment history. Treat-
ment history included initial and subsequent medication regi-
mens. Changes in medication regimens were categorized by
failure to reach or maintain target pressure, adverse effects, disc
and visual ﬁeld progression, compliance, surgery or surgical
failure, and other reasons. Descriptive statistics were used to
analyze patient demographics and distributions by study vari-
ables. RESULTS: Among the 745 patients, there were 2049
changes in treatment during the study period. Frequency of treat-
ment changes were failure to reach target pressure (29%), failure
to maintain target pressure (17%), adverse effects (20%),
surgery (11%), failure of surgery (5%), disc progression (5%),
visual ﬁeld progression (5%), compliance (3%), and other
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reasons (6%). Discontinuations due to adverse events were: 
brimonidine (44.7%), dorzolamide/timolol ﬁxed combination
(25.9%), travoprost (14.7%), bimatoprost (13.9%), timolol
(11.0%), latanoprost/timolol ﬁxed combination (8.6%), and
latanoprost (8.4%). CONCLUSIONS: Changes in treatment
were most often associated with efﬁcacy (failure to reach or
maintain target pressure) and adverse effects. Discontinuations
of therapy were greatest with brimonidine and lowest with
latanoprost. Latanoprost and latanoprost ﬁxed combination
exhibited fewer discontinuations as a result of adverse effects in
comparison to timolol or other prostaglandin monotherapies.
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OBJECTIVE: This study examines mean days between patients
reﬁlling their glaucoma prescriptions for latanoprost, travoprost,
and bimatoprost. METHODS: Patients with an initial NDC
pharmacy claim for the 2.5mL bottle of latanoprost, travoprost,
or bimatoprost between September, 2002 and December, 2002
were identiﬁed from a retail pharmacy database. Continuous 
eligibility was deﬁned by at least one claim for the same lipid
agent and bottle size one year later between October, 2003 and
December, 2003. The mean number of days between claims,
mean number of reﬁlls, the average cost per patient per year and
the annual reﬁll cost differences between cohorts were calcu-
lated. Due to limitations inherent in claims data analyses, efﬁ-
cacy data were not part of the analysis. RESULTS: The mean
number of days between reﬁlls for latanoprost was 47, for travo-
prost 53, and for bimatoprost 52. The among-group difference
was statistically signiﬁcant (p < 0.0001). The mean number of
reﬁlls per year was calculated to be 7.8, 6.9, and 7.0 for
latanoprost, travoprost, and bimatoprost, respectively. Based on
the mean number of reﬁlls, the average cost per patient per year
was $429.11 for travoprost, $434.70 for bimatoprost, and
$455.36 for latanoprost. The incremental reﬁll cost savings per
year for the latanoprost population (n = 79,820) would be
approximately $2 million by using bimatoprost or travoprost
instead of latanoprost. CONCLUSIONS: Both bimatoprost and
travoprost have higher average days between reﬁlls, suggesting
these two products may last longer than latanoprost. Conse-
quently, an additional reﬁll cost savings is realized by using
bimatoprost or travoprost over latanoprost.
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OBJECTIVES: It is estimated that 1.2 million cataract surgeries
are performed annually in the United States. Cataract patients
bilaterally implanted with monofocal intra-ocular lenses (M-
IOLs) often remain partially dependent on spectacles. Bilateral
implantation of apodized diffractive multifocal IOLs (ADM-
IOLs) substantially reduce postoperative spectacle dependence.
The objective of this study was to determine the value of the
ADM-IOL relative to the M-IOL based on patient willingness-
to-pay (WTP) for spectacle independence. METHODS: The eco-
nomic beneﬁt of spectacle independence was valued using a WTP
approach. The Cataract TyPE Speciﬁcation was used to collect
WTP for spectacle independence in a large clinical trial compar-
ing ADM-IOLs to M-IOLs. A cost-beneﬁt analysis (CBA) was
used to determine the net beneﬁt of spectacle independence for
ADM-IOL and M-IOL patients. Net beneﬁt was deﬁned as
patient WTP for spectacle independence, weighted by the prob-
ability of achieving spectacle independence, minus the incre-
mental cost of treatment. Cost information was taken from
standard reference sources and presented from a societal per-
spective. The incremental cost of the ADM-IOLs was set at
$1200. Costs and beneﬁts were discounted at 3%. The time-
frame of the study was 14 years based on patient life expectancy.
RESULTS: The clinical trial established that ADM-IOL patients
had an 80% probability of achieving spectacle independence
compared to only 8% for M-IOL patients. The vast majority of
the trial subjects (80%) indicated a daily WTP of ≥$5.00 for
spectacle independence. Based on these results, the ADM-IOL
net beneﬁt was estimated at $13,802 compared to a net beneﬁt
of $1,371 for the M-IOL. CONCLUSIONS: This study indicated
that cataract patients place a high value on spectacle indepen-
dence. Consequently, the net beneﬁt of the ADM-IOL was 11.5
times greater than its incremental cost and nine times greater
than the beneﬁt provided by the M-IOL.
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OBJECTIVES: Glaucoma is the second leading cause of bilateral
blindness worldwide. Early detection and treatment can prevent
the occurrence of blindness. The objective of this study is to
determine the most cost-effective case-ﬁnding strategy to detect
and treat ocular hypertension (OH) and primary open-angle
glaucoma (POAG) by the ophthalmologist to prevent blindness.
METHODS: An elevated intraocular pressure (IOP) deﬁnes 
OH and is a major risk factor for POAG. IOP is assessed by
tonometry. Three case-ﬁnding strategies, which differ with
respect to the group of patients receiving tonometry, are analyzed
and compared using a Markov cost-effectiveness model. All
patients undergo ophthalmoscopy to detect a glaucomatous
optic nerve, but tonometry is routinely performed to: 1) all newly
visiting patients; 2) high-risk patients only; or 3) no one. The
population characteristics are based on the literature and on data
gathered from the charts of 1000 new patients visiting an 
ophthalmic practice. Transition probabilities are taken from the
literature. The (direct) costs of diagnosis and treatment represent
those for The Netherlands. The time-horizon of the model is 
20 years. An annual discount rate of 4% is used. RESULTS:
Strategy three is cheapest but also yields most blindness. For
strategy one, the computed extra costs to prevent one person
from blindness amount to 7800€. For strategy two this is
19,500€. The marginal C/E ratio for strategy one is 1670€ per
year of vision saved; for strategy two this is 4250€. These out-
comes disregard extra costs due to blindness, estimated to exceed
at least 5000€ per year of blindness. Strategy one is computed
to become cost saving when such costs exceed 1700€. Extensive
sensitivity analyses show that these results are robust. CON-
CLUSION: It is cost-effective to routinely perform tonometry 
to all new ophthalmic patients to prevent blindness due to 
glaucoma.
